Table 1.
Demographics and clinical characteristics of the study population
| Characteristics | Overall patients, n = 84 |
|---|---|
| Sex | |
| Female/male | 30/54 |
| Age | |
| ≤ 60 years/> 60 years | 43/41 |
| LDH | |
| Normal/higher than normal | 38/46 |
| B symptoms | |
| No/yes | 33/51 |
| ECOG performance status | |
| 0–1/> 1 | 57/27 |
| Ann arbor stage | |
| I–II/III–IV | 15/69 |
| Extranodal sites ≥ 2 | |
| No/yes | 65/19 |
| BMB | |
| Negative/positive | 63/21 |
| Ki-67 ≥ 80% | |
| No/yes | 60/24 |
| Platelet cell count ≥ 150 × 109/L | |
| No/yes | 48/36 |
| IPI | |
| 0–2/3–5 | 47/37 |
| PIT | |
| 0–1/2–4 | 41/43 |
| IPTCLP | |
| 0–1/2, 3 | 54/30 |
LDH lactate dehydrogenase, ECOG PS Eastern Cooperative Oncology Group performance status, BMB bone marrow biopsy, IPI International Prognostic Index, PIT prognostic index for T-cell lymphoma, IPTCLP International peripheral T cell lymphoma Project